// App-Quantinova.ai

TPS8579 : CheckMate 451: A randomized, double-blind, phase III trial of nivolumab (nivo), nivo plus ipilimumab (ipi), or placebo as maintenance therapy in patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC) after first-line platinum-based doublet chemotherapy (PT-DC).

Researchers

Presenter

  • Neal Ready

Principal Investigators

  • Taofeek Kunle Owonikoko

  • Pieter E. Postmus

  • Martin Reck

  • Solange Peters

  • Anne Pieters

  • Giovanni Selvaggi

  • Justin P. Fairchild

  • Ramaswamy Govindan

Medical Centers

  • Duke University Medical Center, Durham, NC

  • Emory University, Atlanta, GA

  • University of Liverpool, Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom

  • Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), member of the German Center for Lung Research (DZL), Grosshansdorf, Germany

  • University Hospital Vaud, Lausanne, Switzerland

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Washington University School of Medicine, St. Louis, MO

Locations

  • United States

  • Germany

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Small cell lung cancer

Biomarkers

  • N/A

Drug/Treatment

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT02538666

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved